FORMULATION AND EVALUATION OF GASTRO RETENTIVE FLOATING TABLETS OF GLICLAZIDE by Thakkar Hardik Kumar Rajeshbhai et al.
Thakkar Hardik Kumar Rajeshbhai et al / IJRAP 2011, 2 (4) 1368-1373 
International Journal of Research in Ayurveda & Pharmacy, 2(4), 2011  1368-1373 
Research Article    Available online through     
  www.ijrap.net  ISSN 2229-3566 
 
FORMULATION AND EVALUATION OF GASTRO RETENTIVE FLOATING TABLETS 
OF GLICLAZIDE 
Thakkar Hardik Kumar Rajeshbhai
*, A. Senthil, Chavda Gajendrasinh A, Patel Jyotindra N, 
Narayanswamy V.B. 
Karavali College of Pharmacy, Mangalore, Karnataka, India 
 
Received on: 11/06/2011 Revised on: 20/07/2011 Accepted on: 10/08/2011 
 
ABSTRACT 
A  gastro  retentive  floating  drug  delivery  system  containing  gliclazide  was  prepared  in  the  form  of  tablet  and 
evaluated for its processing parameters and in vitro release behaviour. Gliclazide is a selective second-generation 
sulphonyl urea used in treatment of hyperglycemia and it absorbs rapidly and completely. However its absorption is 
erratic in diabetic patient due to its impaired gastric motility or gastric emptying. To overcome these drawbacks, the 
present investigation was to develop a gastro retentive floating tablets of gliclazide. Ten formulations containing 
retardant materials such as hydroxypropylmethylcellulose K4M and K15M, sodium bicarbonate was used as a gas 
generating agent to reduce floating lag time and other release promoters. Tablets remained buoyant over 12 hours in 
the release medium, and the amount of sodium bicarbonate found to be significant for not only to remaining buoyant 
without causing disintegration of the tablet, but also to release of the drug in the acidic medium. Final F6 optimized 
formulation released approximately 99% drug in 12 hours in vitro, while the floating lag time was 39 sec and tablet 
remained floatable throughout all studies. In vitro gastro retentive study of tablets gave successful results by floating 
in gastric content over a period of 24 hours. The results of the current study clearly indicate, a promising potential of 
the gliclazide floating system as an alternative to the conventional dosage form. 
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INTRODUCTION 
During  the  last  decade,  many  studies  have  been 
performed concerning the sustain release dosage forms 
of drug, which have aimed at the prolongation of gastric 
emptying time (GET). The GET has been reported to be 
from 2 to 6 hours, in humans in fed state.
1 Retention of 
drug  delivery  system  in  the  stomach  prolongs  overall 
gastro  intestinal  transit  time,  thereby  resulting  in 
bioavailability. Drugs that required to be formulated into 
gastro  retentive  dosage  forms  include,  drugs  acting 
locally and primarily absorbed in stomach, drugs that are 
poorly  soluble  at  an  alkaline  pH, those  with  a  narrow 
window of absorption, drugs absorbed rapidly from GI 
tract  and  drugs  that  degrade  in  colon.
1  Scientigraphic 
studies determining gastric emptying rates revealed that 
orally administered controlled release dosage forms were 
subjected  to  basically  two  complication;  that  of  short 
gastric  residence  time  and  unpredictable  gastric 
emptying rate. Various approaches have been worked out 
to improve the retention of oral dosage forms: swelling 
and expanding system,
2 alter dosage forms,
3 low density 
or floating drug delivery system,
2 bioadhesive system,
4 
high  density  non-floating  drug  delivery  system,
5 
modified shaped system.
5 Depending on the mechanism 
of  buoyancy,  two  distinctly  different  methods  viz., 
effervescent and non-effervescent system have been used 
in  the  development  of  floating  drug  delivery  system 
(FDDS).
6  Effervescent  drug  delivery  system  utilize 
matrices  prepared  with  swellable  polymers  such  as 
methocel
5  or  polysaccharides  and  effervescent 
components e.g., sodium bicarbonate and citric acid or 
tartaric acid.
7 
Gliclazide is a selective second generation sulphonylurea 
used  in  the  treatment  of      hyperglycemia.  It  is  poorly 
soluble in the acidic environment. When it is given orally 
in  healthy  people,  it  absorbs  rapidly  and  completely. 
However, its absorption is erratic in diabetic patients due 
to the impaired gastric motility or gastric emptying. This Thakkar Hardik Kumar Rajeshbhai et al / IJRAP 2011, 2 (4) 1368-1373 
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erratic  absorption  of  gliclazide  is  clinically  relevant, 
since  the  efficacy  of  short  acting  sulphonylurea  is 
dependent  upon  the  absorption  rate  of  the  drug.
8  To 
overcome these drawbacks, in the present study gastric 
retentive controlled release dosage form of the drug in 
the  form  tablet  was  formulated  with 
hydroxypropylmethylcellulose K4M and K15M as both 
retardant  and  low  density  materials.  The  aim  of  the 
present study was not only preparing a floating system 
but  also  to  release  the  drug  in  controlled  fashion. 
Polymers  were  added  in  different  concentrations  with 
varying amount of retardant material and investigated the 
release profile following USP type II in vitro dissolution 
model. 
MATERIALS AND METHODS 
Materials 
Gliclazide was obtained as gift sample from Aurobindo 
pharmaceuticals,  Hyderabad,  India.  Polyvinyl 
pyrrolidone and Sodium lauryl sulfate was obtained from 
Loba  Chemie,  Pvt,  Ltd,  Mumbai. 
Hydroxypropylmethylcellulose  K15M  and  K4M  were 
purchased from Madras pharmaceuticals, Chennai. Other 
reagents and solvents were of analytical grade. 
METHODS 
Preparation  of  gastro  Retentive  floating  tablets  of 
gliclazide 
Gastro  retentive  floating  tablets  of  gliclazide  were 
prepared  by  direct  compression  method.  The  powder 
mixture  containing  drug,  polymers  (HPMC  K4M  and 
HPMC K15M) and other excipients including talc 1% as 
lubricant was  blended thoroughly  in  mortar and pestle 
and passed through sieve no. 100. Then the mixture was 
compressed using 8mm flat faced punch on Cemach 12 
station  rotator  tablet  compression  machine.  Ten 
formulations were prepared and coded them F1 to F10. 
The detail of composition of each formulation is given in 
Table 1. 
EVALUATION OF GRANULES 
Angle of repose  
Angle of repose were determined using funnel method.
9 
The blend was poured through a funnel that can be raised 
vertically until a maximum cone height (h) was obtained.  
Radius of the heap (r) was measured and the angle of 
repose (Q) was calculated using the formula. 
Q = tan
-1 (h/r) 
Bulk density 
Apparent bulk density (pb) were determined by pouring 
the blend in to a graduated cylinder.  The bulk volume 
(Vb) and weight of the powder (M) was calculated using 
the formula.
9 
pb = M/ Vb 
 
Tapped density 
The  measuring  cylinder  containing  a  known  mass  of 
blend  was  tapped  for  a  fixed  time.    The  minimum 
volume (Vt) occupied in the cylinder and the weight (M) 
of the blend were measured. The tapped density (ρt)
9 was 
calculated using formula. 
ρt = M/ Vt 
Compressibility index 
The simplest way for measuring of free flow of powder 
was compressibility, an indication of the ease with which 
a  material  can  be  induced  to  flow  is  given  by 
compressibility index (I)
9 was calculated as follows. 
I = V0 - Vt /VO × 100 
Where, Vo is the bulk volume and Vt is tapped volume.   
Hausner’s ratio 
Hausner’s ratio
10 was an indirect index of ease of powder 
flow. It was calculated by the following method  
Hausner ratio = ρt /ρd 
Where,  ρt  tapped  density  and  ρd  bulk  density  lower 
hausner ratio. 
Weight variation 
Twenty  tablets  were  selected  randomly  from  each 
formulation and weighed individually using an electronic 
balance  to  check  the  weight  variations  as  per 
pharmacopoeia.
9 
Friability 
Friability  of  the  tablets  was  determined  using  Roche 
friabilator.  
Hardness 
Hardness of the tablets was  measured using Monsanto 
tablet hardness tester for each formulation.
9 
Thickness 
10 tablets were taken  from each  formulation and their 
thickness was measured using digital vernier calipers. 
Drug content estimation  
According  to  literature  review  the  assay  for  second 
generation  oral-anti  diabetic  drugs  like  gliclazide  was 
estimated  by  ultraviolet  visible  (UV/VIS) 
spectrophotometric  method.  Aqueous  solution  of  drug 
was  prepared  in  phosphate  buffer  (pH  6.8)  and 
absorbance  is  measured  on  ultraviolet  visible 
spectrophotometer at 229 nm. 
In vitro dissolution studies 
The dissolution study was carried out in phosphate buffer 
(pH  6.8)  using  USP  XXIII  dissolution  test  apparatus 
employing paddle stirrer. In this study, tablet gliclazide 
was placed inside the 900 mL dissolution medium and 
speed of paddle was set at 100 rpm. Samples  were (5 
mL) withdrawn at a time  interval of 1 hour and same 
volume of fresh medium was replaced. The samples were 
analyzed for drug content against phosphate buffer as a Thakkar Hardik Kumar Rajeshbhai et al / IJRAP 2011, 2 (4) 1368-1373 
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blank  at  229  nm.  The  percentage  drug  release  was 
plotted against time to determine the release profile.  
In vitro buoyancy studies 
The in vitro  buoyancy was determined  by  floating  lag 
time, as per the method described by (Rosa M, Zia H, 
Rhodes T 1994). The tablets were placed in a 100 mL 
beaker containing 0.1 N HCl. The time required for the 
tablet to rise to the surface and float was determined as 
floating lag time. 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR studies were performed on drug, excipient and the 
optimized  formulation  using  FTIR.    The  sample  were 
analysed between wave numbers 4000 and 400 cm
-1. 
RESULTS 
The  shape  of  the  tablets  of  all  formulations  remained 
circular with no visible cracks. The content uniformity 
test  (Table  3)  revealed  that  the  tablets  from  different 
formulations remained within the pharmacopoeial limit. 
Also the tablets remained buoyant for a period of > 24 
hrs. The formulations exhibited good flow property and 
compressibility  index  (Table  2).  Angle  of  repose  and 
compressibility  index  (%)  ranged  from  26.73  to  29.30 
and  11.26
  to  15.90,  respectively.  Drug  content  was 
ranged  from  97.2%  to  101.12%.  The  thickness  of  the 
tablets ranged from 4.38 mm to 4.62 mm. The average 
percentage deviation of 20 tablets from each formulation 
was remained within ± 5%. The average hardness is 5.5 
kg/cm
2 and percentage friability of the tablets of all the 
batches  remained  in  the  range  of  0.47  to  0.91 
respectively.  In  vitro  dissolution  studies  of  the 
formulations  F1,  F2,  F3,  F4  and  F5  the  drug  released 
97%,  released  were  99.7%,  96.4%,  89.9%,  86.6%  and 
79.9%  of  drug  in  12  hours.  These  formulations  are 
similar to the 92%, 86%, 85% and 75% drug respectively 
at  the  end  of  6  hours  were  shown  in  Table  4.  These 
formulations vary in amount and type of polymers used. 
Formulations  F6,  F7,  F8,  F9  and  F10  the  drug 
formulations  mentioned  before  except  the  grade  of 
polymer used. These formulations thus can be compared 
with  the  earlier  formulations  to  study  the  effect  of 
polymers  on  drug  release  rate.  Among  the  all 
formulations F6 was found to be better with respect to 
the release. 
DISCUSSION 
The present study was aimed at not only to improve the 
release of drug, gliclazide, in the acidic pH, but also to 
release the drug in controlled fashion. Also, to make the 
formulation remain in the stomach for longer period of 
time, gastro retentive dosage form was designed, to make 
the  therapy  more  effective  as  the  drug  is  known  for 
incomplete absorption  in diabetic patients as explained 
before. The polymers used  in the  formulation are well 
established polymers for the said dosage form. The roles 
of polymers are to control the release as well as to make 
the formulation buoyant. The tablets were prepared by 
direct compression method after mixing the ingredients 
with  the  help  of  mortar  and  pestle.  The  granules  of 
different  formulations  were  evaluated  for  angle  of 
repose,  compressibility  index,  and  drug  content.  The 
results of angle of repose (26
 to 29) indicate reasonably 
good  flow  property  of  granules.  The  compressibility 
index values in the range of 11.2 to 15.9 (< 25), further 
support flow property of granules. The drug content of 
all  the  formulations  was  found  to  be  more  or  less 
uniform (Table 2). Tablets of all the formulations were 
subjected to many in-process parameters evaluation such 
as  physical  appearance,  thickness,  content  uniformity, 
weight  variation,  hardness,  and  friability  tests.  All  the 
formulations showed thickness in the range of 4.38 mm 
to 4.62 mm. Also the tablets were circular in shape with 
no  visible  cracks  with  smooth  appearance.  Weight 
variation  test revealed  that  the tablets  were  within  the 
range of pharmacopoeial limit. Good uniformity in drug 
content was found among different formulations of the 
tablets, and the percentage drug content was more than 
96%.  All  the  formulations  show  edreasonably  good 
hardness value of 5.5 kg/cm
2 approximately. Further, to 
strengthen  these  values,  friability  test  values  are  also 
considered. The weight loss of less than 1% in friability 
test is considered as  acceptable  value  for conventional 
tablet. This indicates that the tablets can withstand the 
mechanical shocks reasonably well during handling.  
Formulations were prepared by different concentrations 
HPMC K4M and K15M with carbopol 974P polymers. 
All  the  polymers  were  chosen  as  they  are  well 
established in the similar studies and have good swelling 
properties. The rate of swelling of polymer depends upon 
the  amount  of  water  taken  up  by  polymer.  Sodium 
bicarbonate  is  added  in  the  formulation  which  upon 
contact  with  HCl  liberates  carbon  dioxide  and  expels 
from  the  dosage  form  creating  pores  through  which 
water  can  penetrate  in  to  dosage  form  and  increase 
wetting.  As  the  concentration  of  HPMC  K4M  and 
HPMC K15M increased from 30 mg to 70 mg the release 
rate  was  decreased.  Theoretically  speaking  this 
behaviour  is  expected  since  more  amount  of  polymer 
always delays the release (Figure 1 and 2). The amount 
of sodium bicarbonate in formulation is also believed to 
play a very important role as far as the drug release is 
concerned.  Besides  its  buoyancy  effect  due  to  the 
liberation of CO2 and subsequent entry of water through 
pores increase the wetting rate of polymers as well as the 
alkalizing effect of sodium bicarbonate contributes to the 
solubility of the drug better in all the formulation. All the Thakkar Hardik Kumar Rajeshbhai et al / IJRAP 2011, 2 (4) 1368-1373 
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formulations were designed as dosage form for 12 hours. 
In order to check the 100% dissolution release profile, 
optimized  formulations  were  subjected  to  dissolution 
studies  for  12  hours.  Among  the  ten  formulations  F6 
formulation was best and shows 99% drug release in the 
end of 12 hours, respectively. Figure 2 shows the drug 
release  profiles  of  these  optimized  formulations.  FTIR 
spectra  revealed  that  there  was  no  such  interaction 
between the drug and the polymers used for microsphere 
formulations.  
CONCLUSION 
The present study was carried out to develop the floating 
drug delivery with controlled release of gliclazide tablets 
using two different polymers HPMC K4M and HPMC 
K15M at different concentrations. As the concentration 
of polymer increased floating lag time decreased. Use of 
high viscosity polymer can also decrease the floating lag 
time  and  viscosity  of  polymer  should  directly 
proportional relationship with swelling characteristics of 
tablets.  This  may  overcome  solubility  problems  and 
clinical  problems  associated  with  gliclazide  showed 
sufficient release for extended period of time. As a result 
the frequent dosing and possible incomplete absorption 
of  drug  can  be  avoided.  The  prepared  tablets  were 
evaluated  and  all  the  formulations  gave  satisfactory 
results.  Hence  it  was  concluded  that  the  formulations 
with HPMC K15M was optimized for better release.  
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TABLE 1. COMPOSITION OF GLICLAZIDE FLOATING TABLET 
FORMULATIONS 
Ingredients  F 1  F2  F 3  F 4  F 5  F 6  F 7  F 8  F 9  F 
10 
Gliclazide  10  10  10  10  10  10  10  10  10  10 
HPMC K4M  70  60  50  40  30           
HPMC K15M            70  60  50  40  30 
Carbopol  
974P  30  40  50  60  70  30  40  50  60  70 
Sodium 
bicarbonate  35  35  35  35  35  35  35  35  35  35 
MCC  52  52  52  52  52  52  52  52  52  52 
Magnesium 
stearate  2  2  2  2  2  2  2  2  2  2 
Talc  1  1  1  1  1  1  1  1  1  1 
Total Weight 
(mg)  200  200  200  200  200  200  200  200  200  200 
 
TABLE 2. EVALUATION OF GRANULES 
Formulations  Angle of 
Repose (Q) 
Compressibility 
Index (%) 
Hausner 
Ratio 
F1  28
0. 70’  12.3  1.15 
F2  29
0. 32’  15.9  1.19 
F3  27
0. 64’  12.8  1.13 
F4  28
0. 10’  15.7  1.17 
F5  28
0. 46’  12.4  1.14 
F6  27
0. 90’  11.2  1.13 
F7  26
0. 74’  12.3  1.18 
F8  28
0. 76’  12.3  1.15 
F9  29
0. 36’  15.9  1.19 
F10  27
0. 60’  12.8  1.13 
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TABLE 3. EVALUATION OF GLICLAZIDE FLOATING TABLETS 
 
Formulations  Weight 
(mg)  Hardness (kgs)  Friability  Thickness 
(mm) 
Drug Content 
(%) 
Floating Lag 
Time (sec) 
Floating 
Time 
(hours) 
F1  200.8 ± 0.74  6.1 ± 0.3  0.65 ± 0.11 %  4.55 ± 0.09  99.01 ± 1.2 %  19  18 
F2  194.6 ± 0.33  5.8 ± 0.3  0.71 ± 0.15  %  4.38 ± 0.06  101.02 ± 3.2 %  18  16 
F3  201.7 ± 0.14  5.6 ± 0.2  0.81 ± 0.21 %  4.49 ± 0.03  98.2 ±  2.5 %  16  16 
F4  205.9 ± 0.28  5.4 ± 0.2  0.89 ± 0.45 %  4.58 ± 0.03  97.28 ± 3.1 %  14  15 
F5  197.3 ± 1.14  5.1 ± 0.6  0.91 ± 0.10 %  3.48 ± 0.05  99.12 ± 0.5 %  13  15 
F6  207.6 ± 0.85  6.1 ± 0.7  0.47 ± 0.05 %  4.60 ± 0.03  102.06 ± 0.9 %  39  >  24 
F7  201.4 ± 1.01  5.9 ± 0.1  0.54 ± 0.12 %  4.46 ± 0.01  100.07 ± 3.5 %  30  >  24 
F8  195.1 ± 0.52  5.8 ± 0.4  0.63 ± 0.11 %  4.62 ± 0.06  100.01 ± 3.4 %  24  > 24 
F9  198.2 ± 0.34  5.5 ± 0.2  0.69 ± 0.14 %  4.48 ± 0.03  99.01 ± 0.8 %  20  > 24 
F10  202.1 ± 0.48  5.4 ± 0.4  0.71 ± 0.21 %  4.45 ± 0.05  101.2 ± 2.4 %  19  > 24 
 
TABLE 4. IN VITRO DRUG RELEASE STUDIES OF FLOATING TABLETS WITH HPMC K4M POLYMER 
 
TIME (hours)  F1  F2  F3  F4 
 
F5 
0.5  22.1 ± 0.6  20.3 ± 1.2  19.4 ± 2.1  16.8 ± 2.5  10.7 ± 1.3 
1  36.8 ± 2.1  29.4 ± 3.1  29.7 ± 1.3  25.8 ± 2.8  22.1 ± 1.2 
2  54.8 ± 1.3  50.4 ± 2.6  48.7 ± 2.6  36.5 ± 3.6  28.2 ± 2.6 
3  75.4 ± 2.3  59.6 ± 1.8  55.6 ± 3.2  49.8 ± 2.1  56.1 ± 3.2 
4  81.3 ± 1.3  74.8 ± 1.6  72.5 ± 2.4  67.7 ± 2.4  64.1 ± 1.5 
6  97.1 ± 2.5  92.0 ± 3.1  86.1 ± 3.5  85.1 ± 1.2  75.1 ± 1.9 
 
TABLE 5. IN VITRO DRUG RELEASE STUDIES OF FLOATING TABLETS WITH HPMC K15M POLYMER 
 
TIME 
(hours) 
F 6  F 7  F 8  F 9 
 
F10 
0.5  14.8 ± 2.5  12.9 ± 3.6  15.4 ± 2.1  10.3 ± 1.5  8.1 ± 1.5 
1  22.7 ± 2.3  20.8 ± 2.5  23.3 ± 1.6  18.8 ± 2.4  16.2 ± 0.8 
2  29.6 ± 2.6  33.7 ± 1.6  28.7 ± 1.5  26.7 ± 1.6  22.5 ± 3.4 
3  45.9 ± 1.4  41.6 ± 2.5  38.6 ± 0.6  42.6 ± 3.4  36.8 ± 2.5 
4  59.5 ± 2.6  63.2 ± 3.6  52.5 ± 2.6  51.0 ± 4.5  48.1 ± 2.6 
6  74.7 ± 3.6  68.0 ± 1.8  66.3 ± 2.6  63.9 ± 2.6  60.8 ± 2.4 
8  83.4 ± 4.5  79.7 ± 3.7  75.1 ± 2.7  72.1 ± 3.6  68.4 ± 3.5 
10  92.1 ± 2.3  85.8 ± 4.5  81.6 ± 3.4  79.2 ± 4.5  75.8 ± 2.1 
12  99.7 ± 2.6  96.4 ± 3.8  89.9 ± 1.4  86.6 ± 2.8  79.9 ± 1.4 
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FIGURE 1. COMPARATIVE DRUG RELEASE PROFILE OF HPMC K4M FORMULATIONS (F1 TO F5) 
 
 
 
FIGURE 2. COMPARATIVE DRUG RELEASE PROFILE OF HPMC K15M FORMULATIONS (F6 TO F10) 
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